Copiktra FDA Approval History
FDA Approved: Yes (First approved September 24, 2018)
Brand name: Copiktra
Generic name: duvelisib
Dosage form: Capsules
Company: Verastem, Inc.
Treatment for: Chronic Lymphocytic Leukemia, Follicular Lymphoma
Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).
Development Timeline for Copiktra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.